Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease

NCT06385886 · View on ClinicalTrials.gov ↗

Study Summary

The goal of this observational study is to help us understand more about the best ways to help individuals living with Sickle Cell Disease (SCD) get the best care. The main question it aims to answer is: How to find individuals unaffiliated from SCD specialist care use three distinct pathways? Once unaffiliated individuals are found using the pathways, Investigators will employ linkage coordinators (trained staff) to engage these patients in care. Participants will be asked to fill out an assessment survey which will cover areas such as previous and current treatment, clinic and hospital experience, pain, and quality of life. Participants will also be given the option of participation in a 1-hour long interview how they feel about treatment for sickle cell disease including clinic experience, pain, and quality of life?

Conditions Studied

Interventions

  • BEHAVIORAL Linkage Coordinator

Study Locations (9)

Alabama

  • University of Alabama, Birmingham (UAB) — Birmingham

Arizona

  • Phoenix Children's Hospital — Phoenix

California

  • University of California, San Francisco (UCSF) — Oakland

Georgia

  • Augusta University — Augusta

Illinois

  • University of Illinois — Chicago

Ohio

  • Cleveland Clinic — Cleveland

Pennsylvania

  • University of Pennsylvania — Philadelphia

Tennessee

  • University of Tennessee at Memphis — Memphis

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2023-06-08
Est. Completion 2027-12

Sponsor

RTI International

41 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06385886

The ClinicalTrials.gov registry entry for NCT06385886 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RTI International, which has 41 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention — of which Linkage Coordinator is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06385886 reports 9 study locations spanning 9 distinct geographic areas — top geographies include Alabama, Arizona, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06385886 about?

NCT06385886 is a clinical study titled "Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease". The goal of this observational study is to help us understand more about the best ways to help individuals living with Sickle Cell Disease (SCD) get the best care. The main question it aims to answer is: How to find individuals unaffiliated from SCD specialist care use three distinct pathways? Once ...

What is the current status of trial NCT06385886?

This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2023-06-08. Estimated completion is 2027-12.

What conditions does trial NCT06385886 study?

This clinical trial studies the following conditions: Sickle Cell Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06385886?

The interventions under investigation include: Linkage Coordinator (BEHAVIORAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06385886?

This trial is sponsored by RTI International, which has 41 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06385886 being conducted?

This trial has 9 study locations across Alabama, Arizona, California, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial